High prevalence of &lt;i&gt;KRAS&lt;/i&gt; and &lt;i&gt;GNAS&lt;/i&gt; mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategies. The gene discussed is KRAS; the disease is pseudomyxoma peritonei.